在适合移植的新诊断多发性骨髓瘤患者中,来那度胺、硼替佐米和地塞米松诱导治疗加用伊沙妥昔单抗(GMMG-HD7):一项开放标签、多中心、随机、活性对照、3期试验的第1部分
这项在德国67个中心开展的开放标签、多中心、随机、活性对照3期试验,纳入660例适合移植的新诊断多发性骨髓瘤患者,比较伊沙妥昔单抗联合来那度胺、硼替佐米、地塞米松与后三者单独诱导治疗的疗效。主要终点为意向治疗人群的微小残留病(MRD)阴性率,联合组为50%(166/331),对照组为36%(117/329),OR 1.82(95%CI 1.33-2.48),p=0.00017。结论认为加用伊沙妥昔单抗提高了MRD阴性率,未发现新的安全性信号。
要点
- 伊沙妥昔单抗联合来那度胺、硼替佐米、地塞米松诱导治疗3个周期,MRD阴性率50% vs 36%(OR 1.82,95%CI 1.33-2.48,p=0.00017)。
- 3级或4级不良事件发生率联合组63%(208/330) vs 对照组61%(199/328),中性粒细胞减少23% vs 7%,感染12% vs 10%。
- 诱导治疗期间共12例死亡,其中联合组1例(感染性休克)和对照组4例(心功能失代偿、肝肾功能衰竭、心脏骤停、药物性肠炎)被认为与治疗相关。
核心结论
- 在适合移植的新诊断多发性骨髓瘤患者中,诱导治疗加用伊沙妥昔单抗提高了MRD阴性率,且未发现新的安全性信号。
研究设计与样本
- 开放标签、多中心、随机、活性对照、3期试验,在德国67个学术和肿瘤执业中心开展,报告第1部分结果。
- 纳入18-70岁、确诊需系统治疗的初治多发性骨髓瘤、WHO体能状态0-2、适合诱导治疗、大剂量美法仑和自体造血干细胞移植及维持治疗的患者。
- 660例患者按1:1随机分配至伊沙妥昔单抗联合来那度胺、硼替佐米、地塞米松组(331例)或来那度胺、硼替佐米、地塞米松组(329例),接受3个42天周期的诱导治疗。
- 主要终点为意向治疗人群经流式细胞术评估的MRD阴性。
主要发现
- 诱导治疗后MRD阴性:伊沙妥昔单抗组166例(50%) vs 对照组117例(36%),OR 1.82(95%CI 1.33-2.48),p=0.00017。
- 至少发生1次3级或4级不良事件:伊沙妥昔单抗组208/330例(63%) vs 对照组199/328例(61%)。
- 3级或4级中性粒细胞减少:伊沙妥昔单抗组77例(23%) vs 对照组23例(7%);3级或4级感染:伊沙妥昔单抗组40例(12%) vs 对照组32例(10%)。
- 诱导治疗期间共12例死亡,其中伊沙妥昔单抗组1例(感染性休克)和对照组4例(心功能失代偿、肝肾功能衰竭、心脏骤停、药物性肠炎)被认为与治疗相关。
- 诱导治疗开始至结束的中位随访时间:伊沙妥昔单抗组125天(IQR 125-131) vs 对照组125天(IQR 125-132)。
关键数值与推荐
- 来那度胺25 mg口服,第1-14天和第22-35天。
- 硼替佐米1.3 mg/m2皮下注射,第1、4、8、11、22、25、29、32天。
- 地塞米松20 mg口服,第1-2、4-5、8-9、11-12、15、22-23、25-26、29-30、32-33天。
- 伊沙妥昔单抗10 mg/kg静脉给药,第1周期第1、8、15、22、29天,第2和第3周期第1、15、29天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed transplantation-eligible multiple myeloma. METHODS: This open-label, multicentre, randomised, active-controlled, phase 3 trial was done at 67 academic and oncology practice centres in Germany. This study is ongoing and divided into two parts; herein, we report results from part 1. Eligible patients were aged 18-70 years; had a confirmed diagnosis of untreated multiple myeloma requiring systemic treatment and a WHO performance status of 0-2; and were eligible for induction therapy, high-dose melphalan and autologous haematopoietic stem-cell transplantation, and maintenance treatment. Patients were randomly assigned (1:1) to receive three 42-day cycles of induction therapy either with isatuximab plus lenalidomide, bortezomib, and dexamethasone (isatuximab group) or lenalidomide, bortezomib, and dexamethasone alone (control group) using a web-based system and permuted blocks. Patients in both groups received lenalidomide (25 mg orally on days 1-14 and 22-35), bortezomib (1·3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29, and 32), and dexamethasone (20 mg orally on days 1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, and 32-33). Isatuximab was given as 10 mg/kg intravenously on days 1, 8, 15, 22, and 29 of cycle 1 and on days 1, 15, and 29 of cycles 2 and 3. The primary endpoint was minimal residual disease (MRD) negativity assessed by flow cytometry, in the intention-to-treat (ITT) population. This study is registered with ClinicalTrials.gov, NCT03617731. FINDINGS: Between Oct 23, 2018, and Sep 22, 2020, 660 patients were included in the ITT analysis (331 in the isatuximab group and 329 in the control group). 654 (99%) patients were White, two were African, one was Arabic, and three were Asian. 250 (38%) were women and 410 (62%) were men. The median age was 59 years (IQR 54-64). MRD negativity after induction therapy was reached in 166 (50%) patients in the isatuximab group versus 117 (36%) in the control group (OR 1·82 [95% CI 1·33-2·48]; p=0·00017). Median follow-up time from start to end of induction therapy was 125 days (IQR 125-131) versus 125 days (125-132). At least one grade 3 or 4 adverse event occurred in 208 (63%) of 330 patients versus 199 (61%) of 328 patients. Neutropenia of grade 3 or 4 occurred in 77 (23%) versus 23 (7%) patients and infections of grade 3 or 4 occurred in 40 (12%) versus 32 (10%) patients. Among 12 deaths during induction therapy, one death due to septic shock in the isatuximab group and four deaths (one cardiac decompensation, one hepatic and renal failure, one cardiac arrest, and one drug-induced enteritis) in the control group were considered treatment-related. INTERPRETATION: Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone for induction therapy improved rates of MRD negativity with no new safety signals in patients with newly diagnosed transplantation-eligible multiple myeloma. FUNDING: Sanofi and Bristol Myers Squibb (Celgene).
引用
- Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022. PMID: 36328040. doi:10.1016/S2352-3026(22)00263-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。